Judge Robert S. Huie in the US District Court for the Southern District of California dismissed the bulk of claims against Dexcom in a Tuesday order. The two surviving claims, alleging fraudulent misrepresentations, both related to Dexcom’s assurances that it was “taking share” of the market for glucose monitors used by Type 2 diabetes patients taking basal insulin.
The glucose monitor manufacturer had a relatively small sales force ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.